| |
Article Title |
Author(s) |
Pages |
|
|
|
Table of Contents
|
|
A6
|
|
|
|
ASTRO - Program Description/Statement of Need
The 2011 Annual Meeting program, presented by preeminent clinicians and researchers, is designed to disseminate new scientific findings and technical advances. Attendees will receive state-of-the-art ...
|
|
A10
|
|
|
|
Continuing Medical Education
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
|
|
A12
|
|
|
|
ASTRO 2011 Officers and Board of Directors
Anthony L. Zietman, M.D., FASTRO, Chairman
|
|
A16
|
|
|
|
Past Presidents
|
|
A18
|
|
|
|
Past Gold Medal Award Recipients
|
|
A22
|
|
|
|
2011 ASTRO Annual Meeting Award Recipients
Vinai Gondi, M.D. (Clinical)
|
|
A25-A26
|
|
|
|
2011 Silver Pin Club 25 Years of Membership
|
|
A28
|
|
|
|
2011 Abstract Reviewers
|
|
A29-A30
|
|
|
|
2011 Fellows
Members of ASTRO are eligible to become a Fellow if they have been part of the Society for at least 15 years, have given significant service to ASTRO and have made a significant contribution to the fi...
|
|
A32
|
|
|
|
2011 Gold Medal Award Recipient
Kie Kian Ang, M.D., Ph.D.
|
|
A33-A34
|
|
|
|
2011 Gold Medal Award Recipient
Bernard J. Cummings, MB, ChB, FASTRO
|
|
A35
|
|
|
|
Five Year Results of a Randomized External Beam Radiotherapy Hypofractionation Trial for Prostate Cancer
Based on the assumption that the α/β ratio for prostate cancer is low at 1.5 Gy, a randomized trial was devised with a dose escalation strategy. We hypothesized that using hypofractionation to deliver...
|
A. Pollack,
G. Walker,
M. Buyyounouski,
E. Horwitz,
R. Price,
S. Feigenberg,
A. Konski,
R. Stoyanova,
C. Ma
et al.
|
S1
|
|
|
|
Preliminary Analysis of 3D-CRT vs. IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial: Toxicity Report
A preliminary analysis of clinical and treatment characteristics associated with acute and late toxicity in men receiving high dose RT on a Phase III RTOG dose escalation trial.
|
J.M. Michalski,
Y. Yan,
D. Watkins-Bruner,
B. Walter,
K. Winter,
J.M. Galvin,
J. Bahary,
G.C. Morton,
M.B. Parliament,
H. Sandler
et al.
|
S1-S2
|
|
|
|
ACCORD12/0405-Prodige 2 Phase III Trial Neoadjuvant Treatment in Rectal Cancer: Results after 3 Years of Follow-up
This study aims at analysis the main clinical results of the ACCORD12 trial in rectal cancer after 3 years of follow-up.
|
J. Gerard,
S. Gourgou-Bourgade,
D. Azria,
I. Martel-Laffay,
C. Hennequin,
P. Etienne,
V. Vendrely,
E. François,
P. Romestaing,
T. Conroy
et al.
|
S2
|
|
|
|
Role of Radiotherapy after Assessment of Residual Bulky Tumor using FDG-PET in Patients with Advanced-stage Hodgkin Lymphoma: Final Report of the GHSG HD15 Trial
The role of additional radiotherapy after chemotherapy for advanced-stage Hodgkin lymphoma is unclear. The German Hodgkin Study Group (GHSG) thus performed the HD15 trial in which advanced-stage Hodgk...
|
H.T. Eich,
C. Kobe,
M. Dietlein,
J. Kriz,
H. Haverkamp,
M. Fuchs,
P. Borchmann,
A. Engert,
R.P. Mueller
et al.
|
S2-S3
|
|
|
|
A Phase II Multi-institutional Study of Postoperative Pelvic Intensity Modulated Radiation Therapy (IMRT) with Weekly Cisplatin in Patients with Cervical Carcinoma: Two Year Efficacy Results of the RTOG 0418
RTOG 0418 was a Phase II study designed to determine the transportability of pelvic IMRT to a multi-institutional setting. The results of the primary endpoint and secondary endpoint on short term bowe...
|
L. Portelance,
J. Moughan,
A. Jhingran,
B.E. Miller,
M.R. Salehpour,
D. D'Souza,
M. Haddock,
M. Rotman,
D.K. Gaffney
et al.
|
S3
|
|
|
|
RTOG 0822: A Phase II Study of Preoperative (PREOP) Chemoradiotherapy (CRT) Utilizing IMRT in Combination with Capecitabine (C) and Oxaliplatin (O) for Patients with Locally Advanced Rectal Cancer
The current treatment standard for locally advanced rectal cancer is preop CRT followed by surgery and postoperative chemotherapy. Modern approaches of preop CRT intensification have led to increased ...
|
M. Garofalo,
J. Moughan,
T. Hong,
J. Bendell,
A. Berger,
F. Lerma,
R. Lee,
P. Anne,
N. Sharma,
C. Crane
et al.
|
S3-S4
|
|
|
|
Brachytherapy Boost in Loco-regionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Trial of the International Atomic Energy Agency
To determine whether brachytherapy boost after standard external beam radiation and chemotherapy improves outcome in patients with locally advanced nasopharyngeal carcinoma.
|
E. Rosenblatt,
M. El-Gantiry,
I. Elattar,
M. Afiane,
N. Benjafaar,
S. Abubaker,
Y. Chansilpa,
B. Vikram,
M. Abdel-Wahab,
P. Levendag
et al.
|
S4-S5
|
|
|
|
A Phase III Randomized Trial of Intermittent vs. Continuous Androgen Suppression for PSA Progression after Radical Therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013)
Intermittent androgen suppression (IAS) for PSA recurrence after radical radiotherapy (RT) may improve quality of life (QOL) and delay hormone resistance (HR) but has an unknown effect on survival. We...
|
J.M. Crook,
S. Malone,
E. Horwitz,
D. Dearnaley,
G. Duncan,
P. Warde,
M. Gospodarowicz,
K. Ding,
C. OCallaghan,
L. Klotz
et al.
|
S5
|
|
|
|
Long-term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Concurrent Chemoradiation with 5-FU-mitomycin Yields Better Disease-free and Overall Survival than 5-FU-cisplatin
On initial publication of GI Intergroup RTOG 98-11, concurrent chemo-radiation (CCRT) with 5-FU+mitomycin (MMC) decreased colostomy failure (CF) when compared with induction plus concurrent 5-FU+cispl...
|
L.L. Gunderson,
K.A. Winter,
J.A. Ajani,
J.E. Pedersen,
A.B. Benson,
C.R. Thomas,
R.J. Mayer,
M.G. Haddock,
T.A. Rich,
C.G. Willett
et al.
|
S5-S6
|
|
|
|
Meta-analysis of the Impact of Androgen Deprivation Therapy on Cardiovascular Death in Patients with Prostate Cancer
Androgen Deprivation Therapy (ADT) improves outcomes in men with aggressive prostate cancer, but whether it causes excess cardiovascular death is controversial. We performed a meta-analysis of randomi...
|
P.L. Nguyen,
Y. Je,
F.A.B. Schutz,
K.E. Hoffman,
J.C. Hu,
J.A. Beckman,
T.K. Choueiri
et al.
|
S6
|
|
|
|
Lack of Radiation-induced Pulmonary Toxicity 25 years after Treatment with Breast Conservation Therapy or Mastectomy for Early-stage Breast Cancer: Results from the NCI Randomized Trial
The purpose of this study was to assess pulmonary toxicity 25 years after early breast cancer treatment in patients from the National Cancer Institute (NCI) randomized trial of modified radical mastec...
|
B. Simone,
C.B. Simone,
T.D. Dan,
D. Ly,
E. Lita,
S. Smith,
S. Levine,
L. Folio,
N.L. Simone
et al.
|
S6-S7
|
|
|
|
Early Toxicity Results with 3-D Conformal External Beam Therapy (CEBT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial
APBI is now being used clinically and is being evaluated in six clinical trials in which several forms of fractionated external beam for APBI are being used. Recent publications and presentations from...
|
T.B. Julian,
J.P. Costantino,
F.A. Vicini,
J.R. White,
K.A. Winter,
D.W. Arthur,
R.R. Kuske,
R. Rabinovitch,
W.J. Curran,
N. Wolmark
et al.
|
S7
|
|
|
|
Updated Toxicity Results of Three-dimensional Conformal Accelerated Partial Breast Irradiation
Two recent reports of late sequelae after accelerated partial breast irradiation (APBI) suggest that the three dimensional conformal radiation therapy (3D-CRT) technique used to treat the majority of ...
|
K.L. Leonard,
J.T. Hepel,
J.R. Hiatt,
L.L. Price,
T.A. DiPetrillo,
D.E. Wazer
et al.
|
S7-S8
|
|
|
|
Accelerated Partial Breast Irradiation with Low Dose Rate (LDR) Interstitial Implant Brachytherapy (APBI-IB) after Wide Local Excision (WLE): Ten Year Results from a Prospective Trial
To evaluate long term toxicity, cosmesis and local control of patients receiving dose-escalated APBI-IB alone after WLE for early stage breast cancer (bca).
|
J.A. Hattangadi,
M. Ancukiewicz,
S.M. MacDonald,
M.A. Alm El-Din,
M.A. Gadd,
B.L. Smith,
S.N. Powell,
A.G. Taghian
et al.
|
S8-S9
|
|
|
|
Preoperative Breast MRI Influences Patient Selection for Partial Breast Irradiation
The majority of women diagnosed with early stage breast cancer are candidates for breast conserving therapy. One of the options for radiation treatment following breast conserving surgery is partial b...
|
K.V. Kowalchik,
L.A. Vallow,
M. McDonough,
C.S. Thomas,
M.G. Heckman,
J.L. Peterson,
C.D. Adkisson,
C. Serago,
S.J. Buskirk,
S.A. McLaughlin
et al.
|
S9
|
|
|
|
Feasibility of Hypo-fractionated Boost in the Radiation Treatment of Breast Cancer after Conservative Surgery: Acute and Chronic Toxicities in 110 Patients
Hypo-fractionated radiation has become standard in a broad number of patients with breast cancer after conservative surgery. Some of the largest studies do not include a boost or was performed by stan...
|
X. Sanz,
N. Rodriguez,
P. Foro,
A. Reig,
E. Fernández-Velilla,
J. Lozano,
I. Membrive,
P. Iglesias,
J. Lio,
M. Algara
et al.
|
S9-S10
|
|
|
|
Three-year Outcomes of 490 Patients Treated with Accelerated Intensity Modulated Radiotherapy with a Concurrent Boost
To report the NYU 3-year clinical experience of breast radiotherapy using a regimen of accelerated intensity modulated radiation therapy (A-IMRT) with a concurrent boost to the tumor bed.
|
E.O. Osa,
R. Ciervide,
S. Lymberis,
C. Magnolfi,
M. Fenton-Kerimian,
G. Jozsef,
S. Formenti
et al.
|
S10
|
|
|
|
Local Recurrence Outcomes in Phase II Clinical Trial Using Single Dose Intraoperative Radiotherapy (IORT) before Surgical Excision of Early-stage Breast Cancer
To report the 5-year rate of ipsilateral breast recurrence in our study of IORT delivered before tumor excision for patients with early-stage breast cancer.
|
N.A. VanderWalde,
D.W. Ollila,
N.K. DeMore,
D.T. Moore,
R.J. Kimple,
C.M. Kuzmiak,
D. Pavic,
C.I. Sartor,
J. Lian,
E.L. Jones
et al.
|
S10-S11
|
|
|
|
A Prospective Pathologic Study to Define the Clinical Target Volume (CTV) for Partial Breast Radiotherapy in Women with Early Breast Cancer
Partial breast radiotherapy is an emerging paradigm in the treatment of breast cancer but the optimal volume of tissue to irradiate remains uncertain. The purpose of this study is to determine an appr...
|
B.T. Nguyen,
S. Deb,
S. Fox,
P. Hill,
M. Collins,
B. Chua
et al.
|
S11
|
|
|
|
WITHDRAWN
|
|
S11
|
|
|
|
Ki-67 Staining is a Strong Predictor of Patient Outcomes for Prostate Cancer Patients Treated on RTOG 94-08
A series of correlative studies in RTOG high-risk prostate cancer (CaP) trials have found associations between several molecular biomarkers and clinical outcomes. Fewer such studies have taken place i...
|
M.A. Ritter,
Y. Yan,
B. Verhoven,
L. Khor,
E. Hammond,
C.U. Jones,
M.B. Amin,
J. Bahary,
K.L. Zeitzer,
A. Pollack
et al.
|
S11-S12
|
|
|
|
Bladder Preservation Therapy for Muscle-Invading Bladder Cancers (MIBC): Long-term Clinical Outcomes from RTOG 8802, 8903, 9506, and 9706 and Molecular Correlates along the VEGF Pathway
RTOG completed 4 protocols (8802, 8903, 9506, 9706) from 1988 to 1999 treating clinical T2 – 4a MIBC patients with selective bladder preservation using transurethral surgery (TURBT) plus cisplatin-con...
|
A. Chakravarti,
J. James,
J. Efstathiou,
C. Wu,
A. Klimowicz,
H. Sandler,
T. Lautenschlaeger,
W. Tester,
M. Hagan,
W. Shipley
et al.
|
S12
|
|
|
|
Statin Use and Prostate Cancer Recurrence in Men Treated with Brachytherapy
Recent in vitro and in vivo evidence has suggested that statin medications may have anti-cancer activity. We sought to determine whether statin use is associated with improved clinical outcome in men ...
|
D.S. Oh,
H. Song,
S. Freedland,
L. Gerber,
P. Patel,
S. Lewis,
D. Yoo,
J. Oleson,
J.K. Salama
et al.
|
S12-S13
|
|
|
|
Combination Therapy Improves Prostate Cancer Survival for Patients with Potentially Lethal Prostate Cancer: The Impact of Gleason Pattern 5
We recently identified biopsy Gleason pattern 5 (GP5) as the dominant risk factor for metastasis (FFM) and cause specific survival (CSS) in patients treated with dose-escalated external beam radiation...
|
D.A. Hamstra,
E. Abu-Isa,
M.S. Jawad,
F.Y. Feng,
S. Vance,
R. Winfield,
V. Narayana,
H.M. Sandler,
P.W. McLaughlin
et al.
|
S13
|
|
|
|
Prostate HDR Dosimetric Parameters and Treatment Related Toxicity in the Radiation Therapy Oncology Group (RTOG) 0321
RTOG 0321 is the first and only cooperative group prospective HDR prostate brachytherapy trial. It is the only such trial with complete digital brachytherapy dosimetry data. This is a detailed descrip...
|
I.J. Hsu,
D. Hunt,
W. Straube,
J. Pouliot,
J. Cunha,
D. Krishnamurthy,
H. Sandler
et al.
|
S13-S14
|
|
|
|
Interstitial High Dose Rate (HDR) Brachytherapy as Monotherapy for Early-stage Prostate Cancer: Median 8 Year Results in 321 Patients
Transrectal ultrasound (TRUS)-guided interstitial implant for prostate cancer using low dose rate (LDR) and high dose rate (HDR) technique has been reported with results comparing favorably to surgery...
|
R.J. Mark,
D. White,
R. Akins,
S. Mutyala,
M. Nair
et al.
|
S14
|
|
|
|
Favorable Long-term Outcomes with Brachytherapy-based Regimens in Men ≤60 Years with Clinically Localized Prostate Cancer
To report the rate of long term disease and treatment-related outcomes of younger men (< = 60 years) treated with brachytherapy-based radiation therapy for clinically localized prostate cancer.
|
M.A. Kollmeier,
A. Fidaleo,
X. Pei,
Q. Mo,
B. Cox,
Y. Yamada,
M. Zelefsky
et al.
|
S14-S15
|
|
|
|
Distant Metastases following Permanent Interstitial Brachytherapy for Patients with Clinically Localized Prostate Cancer
Recent publications have suggested high-risk patients undergoing radical prostatectomy have a lower risk of distant metastases and improved cause-specific survival (CSS) than patients receiving extern...
|
A.V. Taira,
G.S. Merrick,
R.W. Galbreath,
W.M. Butler,
J. Lief,
E. Adamovich,
K. Wallner
et al.
|
S15
|
|
|
|
IMRT for Oropharyngeal Carcinoma: Patient Outcomes and Patterns of Failure
To report mature results of a large cohort of patients diagnosed with squamous cell carcinoma of the oropharynx that were treated with IMRT.
|
A.S. Garden,
W.H. Morrison,
E.M. Stugis,
L. Dong,
B.S. Glisson,
S.J. Frank,
M.S. Kies,
R.S. Weber,
K.K. Ang,
D.I. Rosenthal
et al.
|
S15-S16
|
|
|
|
Long-term Regional Control in the Observed Neck following Definitive Chemoradiation for Node-positive Oropharyngeal Squamous Cell Cancer
In the past, patients with oropharyngeal squamous cell carcinoma (OPSCC) and advanced stage nodal disease who were treated with definitive chemoradiation underwent a planned post-treatment neck dissec...
|
L. Morris,
A. Goenka,
S. Rao,
S. Wolden,
I. Ganly,
R. Wong,
D. Kraus,
M. Fury,
M. Zelefsky,
N. Lee
et al.
|
S16
|
|
|
|
Defining the Risk of Involvement for Each Neck Nodal Level in Patients with Early T-Stage/Node-positive/HPV-related Oropharyngeal Carcinoma
To assess the risk of ipsilateral subclinical neck nodal involvement for early T-Stage/node positive/HPV-related oropharyngeal carcinoma.
|
G. Sanguineti,
S. Pai,
W. Westra,
A. Forastiere,
J. Califano
et al.
|
S16-S17
|
|
|
|
Low-lying Cervical Metastases Predict for Distant Metastasis in N2 Oropharyngeal Cancer Patients Treated with Intensity Modulated Radiotherapy
To examine the correlation between low-lying cervical metastases and the development of distant metastasis (DM) in oropharyngeal cancer (OPC) treated with IMRT.
|
J. Setton,
S.D. Rao,
M. Lian,
B. Lok,
E. Sherman,
I. Ganly,
R. Wong,
N.Y. Lee
et al.
|
S17
|
|
|
|
Primary Tumor Metabolic Volume Improves Risk Prediction of Long-term Outcomes in Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Intensity Modulated Radiation Therapy (IMRT) and Chemotherapy
T-Stage is an established predictor of poor outcome in patients with oropharynx cancer. We evaluated whether pre-treatment 18F-FDG PET parameters of the primary tumor can further improve risk predicti...
|
R.C. Lim,
H. Schoder,
A. Eaton,
M. Gonen,
S. Rao,
E. Sherman,
R. Wong,
J. Setton,
N. Lee
et al.
|
S17-S18
|
|
|
|
P16 Status in Conjunction with HIF-1α and EGFR Predict Outcomes for p16 Oropharynx Squamous Cell Carcinomas Treated with IMRT
Patients with oropharyngeal squamous cell carcinoma (OPSCC) were treated with Intensity Modulated radiotherapy (IMRT) and stratified by immunohistochemical expression of 8 biomarkers (p16, EGFR, cyclo...
|
A.N. Shoushtari,
D. Wilson,
D. Saylor,
E. Stelow,
C. Thomas,
J. Reibel,
P. Levine,
D. Shonka,
M. Jameson,
P. Read
et al.
|
S18
|
|
|
|
Epidemiological Changes of Oropharyngeal Cancer and other Head and Neck Squamous Cell Carcinomas Treated from 2003 – 2010
There has been a rise in the incidence of oropharyngeal cancer (OPC) with a concomitant decline in other (non-oropharyngeal) head and neck squamous cell carcinomas (NO-HNSCC). This rise in OPC is like...
|
K.P. Chu,
S. Habbous,
S. Huang,
L. Cheng,
W. Xu,
G. Liu,
A. Hope,
F. Liu,
J. Waldron,
B. O'Sullivan
et al.
|
S18
|
|
|
|
Comparative Outcomes and Cost Analysis of Transoral Laser Microsurgery vs. Definitive Radiation Therapy in the Treatment of Oropharyngeal Squamous Cell Carcinoma
Standard treatment options for oropharyngeal squamous cell carcinoma (OPSCC) are surgery and postoperative radiation therapy (RT) ± chemotherapy or definitive chemoradiotherapy (CRT). Transoral Laser ...
|
N.C. Sheets,
A.K. Fortune-Greeley,
B.S. Chera,
P.M. Brown
|
S19
|
|
|
|
Comparison of Cardiac Doses after Involved Node Radiotherapy and Mantle Field Treatment for Hodgkin Lymphoma
The risk of developing cardiovascular disease (CD) for long-term Hodgkin's lymphoma (HL) survivors after mediastinal radiotherapy (RT) is under debate, as current data are, primarily, derived from pat...
|
M.V. Maraldo,
N.P. Brodin,
I.R. Vogelius,
M.C. Aznar,
P. Munck af Rosenschöld,
P.M. Petersen,
L. Specht
et al.
|
S19
|
|
|
|
Active Breath Control to Reduce Normal Tissue Dose in Patients Receiving Mediastinal Radiotherapy for Hodgkin Lymphoma
Combined chemoradiotherapy is the mainstay of treatment for primary early Hodgkin lymphoma (HL). Limiting the toxicity of radiation therapy (RT) while maintaining efficacy is a major clinical goal. Ac...
|
T. Conrad,
C. Coolens,
B. Guibord,
J. San Miguel,
M. Gospodarowicz,
R. Tsang,
A. Sun,
T. Purdie,
D. Letourneau,
D. Hodgson
et al.
|
S20
|
|
|
|
Reducing the Dose to the Cardiac Chambers, Valves, and Vessels with Proton Therapy Compared with 3D-CRT and IMRT in Patients with Mediastinal Hodgkin Lymphoma
In the dosimetric component of a Phase II prospective study of consolidative involved-node radiotherapy (INRT) in patients with mediastinal Hodgkin lymphoma (HL), proton therapy (PT) reduced doses to ...
|
B.S. Hoppe,
S. Flampouri,
Z. Su,
N. Latif,
N. Dang,
J. Lynch,
M. Joyce,
E.S. Sandler,
Z. Li,
N.P. Mendenhall
et al.
|
S20
|
|
|
|
Phase I Dose Escalation Trials of Total Marrow Irradiation (TMI) using Helical TomoTherapy (HT) with Concurrent Full-intensity Chemotherapy in Patients with Advanced Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)
We have shown HT delivers a more targeted form of TBI (TMI). Over 138 patients have been treated to date. Toxicities are acceptable with TMI doses up to 16 Gy and no concurrent chemotherapy or TMI 12 ...
|
J. Wong,
S. Forman,
J. Rosenthal,
G. Somlo,
A. Liu,
T. Schultheiss,
E. Radany,
J. Palmer,
A. Stein
et al.
|
S20-S21
|
|
|
|
Radiotherapy as Predominant Treatment for Stage I/II Extranodal NK/T Cell Lymphoma, Nasal Type: Pattern of Radiotherapy and Treatment Outcome
To investigate parameters of radiotherapy as well as treatment outcome in patients with Stage I/II extranodal natural killer(NK)/T-cell lymphoma who were treated with radiotherapy as predominant treat...
|
Q. Shen,
X. Ma
|
S21
|
|
|
|
Lung Malignancies after Hodgkin Lymphoma: Disease Characteristics, Detection Methods and Clinical Outcome
To analyze the clinical course of patients who developed lung malignancies after Hodgkin lymphoma (HL) therapy.
|
J.D. Schoenfeld,
A.K. Ng,
P. Das,
B. Silver,
P.M. Mauch
et al.
|
S21-S22
|
|
|
|
MicroRNA Profiling of Cutaneous T-cell Lymphoma Cell Lines: Implications for Pathophysiology and Therapy
The presence of circulating malignant T-cells in patients with cutaneous T-cell lymphoma (CTCL) is a poor prognostic factor. Determination of the genetic features that distinguish cutaneous from circu...
|
J.E. Hansen,
F. Reza,
S. Nallur,
J. Lewis,
K.R. Carlson,
W.M. Lin,
J.B. Weidhaas,
L.D. Wilson,
M. Girardi
et al.
|
S22
|
|
|
|
“Large Mediastinal Tumor Mass” is a Prognostic Factor in Hodgkin Lymphoma (HL): Is the Definition on the Basis of a Chest Radiograph in the Era of CT Obsolete?
The risk factor “large mediastinal tumor mass” is an internationally accepted unfavorable prognostic factor for patients with HL. Measurements of the mediastinal mass size on chest radiograph have bee...
|
J. Kriz,
R. Mueller,
H. Mueller,
C. Kobe,
A. Engert,
H. Eich
et al.
|
S23
|
|
|
|
DNA Double-strand Break Repair in the Context of Chromatin
DNA double-strand breaks (DSBs) generated by ionizing radiation represent an extremely cytolethal form of DNA damage and thus pose a serious threat to the preservation of genetic and epigenetic inform...
|
C.E. Ruebe,
Y. Lorat,
S. Schanz,
N. Schuler,
C. Ruebe
et al.
|
S23
|
|
|
|
The Dynamics of Histone Variant H2A.Z upon DNA Damage
Ionizing irradiation induces lethal genome damages like DNA double strand breaks (DSBs) in human cells. Reorganization of damaged chromatin, such as posttranslational modification and/or exchange of h...
|
I. Nishibuchi,
S. Tashiro,
H. Shima,
T. Kimura,
Y. Murakami,
M. Kenjo,
Y. Kaneyasu,
Y. Nagata
et al.
|
S23-S24
|
|
|
|
EGFR Inhibition Radiosensitizes NSCLC Cells via DNA Double-strand Break Inducible Senescence
The subset of patients with Non-small cell lung cancer (NSCLC) sensitive to combined ionizing radiation (IR) and epidermal growth factor receptor (EGFR) inhibitors is not defined. To this end, large c...
|
H. Willers,
M. Wang,
F. Morsbach,
D. Sander,
A. Nanda,
M. Kriegs,
M. Krause,
E. Dikomey,
M. Baumann,
J. Settleman
et al.
|
S24
|
|
|
|
BRCA1 Nuclear Export Sensitizes Prostate Cancer Cells to Poly (ADP-ribose) Polymerase (PARP) Inhibition via the CRM1/exportin Pathway
Poly (ADP-ribose) polymerase (PARP) inhibitors have been shown to be effective in the treatment of tumors with defective homologous recombination (HR). BRCA1 is a protein intimately involved with HR r...
|
L.C. Klepczyk,
S. Nowsheen,
F. Xia,
E.S. Yang
|
S24-S25
|
|
